We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Brian Bergmark

Brian A. Bergmark MD

Investigator, TIMI Study Group and Interventional Cardiologist, Complex Coronary/CTO Program, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massacusetts

Brian Bergmark, MD is an Interventional Cardiologist in the Chronic Total Occlusion/Complex Coronary Intervention Program at the Brigham and Women's Hospital, Harvard Medical School and is an Investigator at the TIMI Study Group. He is an Associate Program Director for the combined Mass General Brigham CTO/Complex Coronary Intervention fellowship. He received his BA from Stanford University and his MD from Harvard Medical School.

Disclosures

Dr. Bergmark reports the following:

  • Research grants (through the Brigham and Women’s Hospital): Pfizer, Ionis, Quark, AstraZeneca/MedImmune, Amgen

  • Consulting/personal fees: Philips, Abbott Vascular, CSI, Abiomed, Servier, Janssen, Quark, Daiichi Sankyo

Dr. Bergmark is a member of the TIMI Study Group, which has received grant support through Brigham and Women’s Hospital from: Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., Daiichi-Sankyo, Eisai, Intarcia, Ionis, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Roche, Siemens Healthcare Diagnostics, Inc., The Medicines Company, and Zora Biosciences.